RDInvesting Provides Investors with Free In-Depth Equity Reports on AMRI, FCSC, GALT and SRNEadmin
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Albany Molecular Research, Inc. (NASDAQ: AMRI) shares declined 4.89 percent to close at $10.89 a share Tuesday. The stock traded between $10.25 and $11.18 on volume of 1.28 million shares traded. Analysts at Sterne Agee have recently downgraded the company’s rating to “neutral” from “buy”. Shares of Albany Molecular Research have gained approximately 105.0 percent year-to-date.
Find out more about Albany Molecular Research including full access to the free equity report at:
Fibrocell Science Inc. (NYSEMKT: FCSC) shares gained 2.70 percent to close at $4.18 a share Tuesday. The stock traded between $4.11 and $4.44 on volume of 144,813 shares traded. Analysts at Wedbush have recently initiated coverage on the company with an “outperform” rating and a price target of $7.00.
Find out more about Fibrocell Science including full access to the free equity report at:
Galectin Therapeutics Inc. (NASDAQ: GALT) shares increased 13.22 percent to close at $8.99 a share Tuesday. The stock traded between $8.34 and $9.42 on volume of 587,888 shares traded. Analysts at MLV & Co. have recently initiated coverage on the company with a “buy” rating. Shares of Galectin Therapeutics have gained approximately 330.0 percent year-to-date.
Find out more about Galectin Therapeutics including full access to the free equity report at:
Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares declined 2.52 percent to close at $8.50 a share Tuesday. The stock traded between $8.50 and $9.75 on volume of 160,911 shares traded. Analysts at Aegis Capital have recently initiated coverage on the company with a “buy” rating.
Find out more about Sorrento Therapeutics including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Posted: December 4th, 2013 under ACCESSWIRE.